Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

A new collaboration in the US between the Patient Advocate Foundation's (PAF) Patient Insight Institute, Gilead Sciences and ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price target for GILD stock.

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Learn more about whether Gilead Sciences, Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corp. (SCHW), ...

Shares of Gilead Sciences ( GILD -1.77%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the ...

Everything you need to know about The Handmaid’s Tale Season 6, including its Hulu release date, cast, plot, and more.

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...

David Furnish’s leadership at EJAF proves brands can do more than raise awareness —they can dismantle stigma and drive ...